Canaccord raised the firm’s price target on Tenaya Therapeutics (TNYA) to $18 from $16 and keeps a Buy rating on the shares. The firm said its 3Q24 earnings report was straightforward, with the more notable news coming earlier in the quarter with the announcement of positive safety updates to cohort 1 of TN-201’s MyPEAK-1 Ph1b/2 clinical trial, and confirmation that more detailed interim data from cohort 1 will come in December.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA: